Replimune Group Inc. – FDA Acceptance of RP1 BLA for Advanced Melanoma

Replimune Group Inc. (NASDAQ: REPL) announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for its lead product candidate, RP1 (vusolimogene oderparepvec), in combination with the checkpoint inhibitor nivolumab for the treatment of advanced melanoma. The acceptance is classified as a complete, class 1 response with an expected review goal date of August 2 2026. The FDA has also scheduled an advisory committee meeting in late July to discuss the risk/benefit profile of RP1.

Context of the Submission

The resubmission seeks accelerated approval based on data from the IGNYTE clinical trial. IGNYTE evaluated RP1 plus nivolumab in patients who had confirmed disease progression after an anti‑PD‑1 regimen. RP1 is an engineered herpes simplex virus type‑1 (HSV‑1) that expresses a fusogenic protein (GALV‑GP R⁻) and granulocyte‑macrophage colony‑stimulating factor (GM‑CSF) to enhance tumor cell killing, immunogenic cell death, and systemic anti‑tumor immune activation.

Advanced melanoma is a highly lethal skin cancer. In the United States, it is estimated that 112,000 new cases will occur in 2026, with approximately 8,500 deaths annually. Standard first‑line therapy relies on immune checkpoint blockade, yet about half of patients fail to respond or experience disease progression. The FDA’s acceptance of RP1’s BLA represents a potential new therapeutic option for this unmet need.

Market Reaction

Following the FDA acceptance, Replimune shares experienced a decline, reflecting market sensitivity to the timing and scope of the forthcoming advisory committee meeting. Despite the drop, JPMorgan upgraded Replimune’s rating and increased its price target, indicating confidence in the company’s pipeline and the strategic positioning of RP1.

Company Perspective

Sushil Patel, Ph.D., CEO of Replimune, stated that the FDA’s expedited action underscores the urgent need for novel therapies in advanced melanoma. The company emphasized its commitment to engaging with the advisory committee and to providing comprehensive data on RP1’s efficacy and safety.

Regulatory Timeline

  • June 26 2026 – FDA accepts the resubmitted RP1 BLA and schedules an advisory committee meeting for late July.
  • August 2 2026 – Targeted date for the FDA’s review response.
  • Late July 2026 – Advisory committee meeting to evaluate RP1’s clinical data.

The acceptance of the BLA aligns with Replimune’s broader strategy to advance its RPx platform, which is engineered to maximize immunogenic cell death and systemic anti‑tumor immunity. The company continues to monitor regulatory developments and is preparing for the forthcoming advisory committee discussion.

Sources: feeds.feedburner.com, www.investing.com , seekingalpha.com, globenewswire.com, www.biopharmadive.com , www.nasdaq.com .